Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene
Public ClinicalTrials.gov record NCT03448081. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Study identification
- NCT ID
- NCT03448081
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Sienna Biopharmaceuticals
- Industry
- Enrollment
- 73 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 11, 2018
- Primary completion
- Nov 20, 2018
- Completion
- Dec 9, 2018
- Last update posted
- Feb 7, 2019
2018
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sienna 018 | Anniston | Alabama | 36207 | — |
| Sienna 009 | Mobile | Alabama | 36608 | — |
| Sienna 019 | Fountain Valley | California | 92708 | — |
| Sienna 007 | Los Angeles | California | 90045 | — |
| Site 016 | Sherman Oaks | California | 91403 | — |
| Site 013 | Coral Gables | Florida | 33143 | — |
| Site 015 | Sanford | Florida | 32771 | — |
| Site 012 | Indianapolis | Indiana | 46256 | — |
| Sienna 011 | Warren | Michigan | 48088 | — |
| Sienna 005 | Berlin | New Jersey | 08009 | — |
| Sienna 020 | Rochester | New York | 14623 | — |
| Site 014 | Raleigh | North Carolina | 27612 | — |
| Sienna 002 | Oklahoma City | Oklahoma | 73118 | — |
| Sienna 017 | Austin | Texas | 78745 | — |
| Sienna 010 | Houston | Texas | 77004 | — |
| Sienna 021 | Pflugerville | Texas | 78660 | — |
| Sienna 001 | San Antonio | Texas | 78213 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03448081, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 7, 2019 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03448081 live on ClinicalTrials.gov.